Management issues in hypertensive diabetics by Ker, JA
Review: Management issues in hypertensive diabetics
144 Vol 53 No 2S Afr Fam Pract 2011
Association between hypertension and 
diabetes
Diabetes mellitus and hypertension are common clinical 
conditions that often co-exist. This combination has 
been called the deadly duet to emphasise the increased 
cardiovascular risk when the two conditions co-exist. 
Hypertension occurs more commonly in diabetics 
than in comparable non-diabetics, as the prevalence 
of hypertension in diabetics is about two times higher 
than that of hypertension as observed in the general 
population. In type 2 diabetes mellitus, hypertension is 
often present as part of a possible common underlying 
metabolic abnormality, such as insulin resistance. 
However, in type 1 diabetes mellitus, hypertension is 
often due to the onset of diabetic nephropathy.
Hypertensive people are 2.5 times more likely to develop 
diabetes mellitus within five years. This may be due to 
the presence of an underlying metabolic syndrome, and 
made worse by the type of antihypertensive drug used, 
e.g. high-dose thiazides combined with high-dose beta 
blockers.
The co-existence of hypertension and diabetes mellitus 
greatly increases the risk for macrovascular and 
microvascular diabetes complications. The presence of 
hypertension causes a 7.2-fold increase and a 37-fold 
increase in mortality in diabetic patients and in diabetic 
nephropathy respectively.
Most patients with diabetes and hypertension will die 
from a cardiovascular cause. Hypertension exacerbates 
all the vascular complications of diabetes, including 
coronary artery disease, renal disease, stroke, peripheral 
artery disease, leg amputations and retinopathy. 
Diabetes increases the risk of coronary artery disease 
twofold in men and fourfold in women, putting women in 
particular, at risk.
Management principles
Intense non-pharmacological measures (lifestyle 
changes) should be encouraged in all diabetic patients 
with attention to weight loss and reduction of salt intake, 
especially in type 2 diabetes. A healthy diet is included in 
lifestyle management.
Blood pressure control is crucial
Data from clinical trials emphasise the need for vigilant 
blood pressure control in patients with diabetes and 
hypertension. In the UK Prospective Diabetes Study 
(UKPDS), each 10 mmHg decrease in mean systolic 
blood pressure was associated with risk reductions of 
12% for any complication relating to diabetes, 15% for 
death, 13% for microvascular complications, and 11% 
for myocardial infarction, respectively. There was no 
threshold of blood pressure where risk was not observed.
What is the blood pressure goal?
A target blood pressure goal < 130/80 mmHg is both 
reasonable and safe to achieve. Both the UKPDS 
and Hypertension Optimal Treatment (HOT) trials 
demonstrated improved outcomes in patients assigned 
to lower blood pressure targets. Epidemiological 
analyses show that blood pressure ≥ 120/70 mmHg is 
associated with increased cardiovascular event rates and 
mortality in patients with diabetes. Achieving lower levels 
will decrease risk, but can be difficult to achieve and will 
increase the cost of treatment and the side-effect profile. 
Control of systolic blood pressure is especially important. 
The Advance Collaborative Group study demonstrated 
the benefit of an angiotensin-converting enzyme (ACE) 
inhibitor and indapamide in a fixed combination, reducing 
blood pressure in diabetics close to the desired goal. 
The study strongly suggests that the blood pressure goal 
(< 130/80 mmHg), as recommended by guidelines, is 
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correct. The ACCORD trial showed that reducing systolic 
blood pressure in diabetics below 120 mmHg had no 
benefit.
The need for multiple-drug therapy
Evidence shows that, to achieve the set goal of 
< 130/80 mmHg, use of multiple-drug antihypertensive 
therapy is required. Agents should be used that have 
been shown to reduce cardiovascular risk, while not 
worsening concomitant conditions, e.g. new onset 
diabetes or abnormal lipids. A renin-angiotensin 
system (RAS) blocker [ACE inhibitor or angiotensin 
receptor blocker (ARB)] should be a component of any 
combination treatment in diabetes.
Blockade of the renin-angiotensin system
It is appropriate that an agent that can block RAS, such as an 
ACE inhibitor or an ARB, should be one of the partner drugs 
used in combination in hypertensive patients with diabetes 
or glucose intolerance. These drugs are also important 
to use if there is microalbuminuria or proteinuria present, 
even if blood pressure is only in the high normal range, 
as they reduce progression to end-stage renal disease. 
Other drugs have also been shown to reduce proteinuria, 
e.g. indapamide and non-dehidropiridine calcium-channel 
blockers (e.g. verapamil).
Which drug to use?
Clinical trials with diuretics, beta blockers, ACE inhibitors, 
ARBs and calcium-channel antagonists have all 
demonstrated benefit in the treatment of hypertension in 
type I diabetes mellitus, as well as type 2 diabetes mellitus. 
This benefit is related to the degree of blood-pressure 
lowering.
The question of which drug is superior has not clearly been 
answered, but an answer is probably not necessary, because 
the hypertensive diabetic will require two or more drugs to 
reach the lower blood pressure target. It is also important 
to evaluate patients for either known complications, 
e.g. coronary artery disease, or other concomitant disease, 
to decide on the best combination of drugs.
The Blood Pressure Lowering Treatment Trialist collaboration 
published a meta-analysis of 27 randomised trials with 
158 709 patients to evaluate the effect of blood-pressure 
lowering on major cardiovascular events in patients with 
and without diabetes mellitus. The results from this meta-
analysis demonstrated that major cardiovascular events 
were reduced to a comparable extent in individuals with 
and without diabetes, by regimens based on ACE inhibitors, 
calcium antagonists, ARBs and diuretic-beta blocker 
combinations. This effect was for short-to-medium term 
duration. There are no data for long-term event reduction. 
The data also did not evaluate specific indications for 
specific drug groups. The implications of this meta-
analysis clearly demonstrate that there is no one particular 
drug that is superior in diabetes and that the majority of 
patients will require two or more drugs to achieve the blood 
pressure goal. Recently, the combination of an ACE inhibitor 
combined with a calcium-channel blocker (amlodipine) was 
shown to be superior to a combination of the same ACE 
inhibitor plus a diuretic in a large group of hypertensive 
patients, and in a sizeable group of diabetic patients.
New-onset diabetes and the use of antihypertensive 
drugs
People with elevated blood pressure levels are 2.5 times 
more likely to develop diabetes mellitus within five years 
than those with normal levels. This phenomenon is made 
worse by the chronic administration of diuretics and beta 
blockers, especially when administered in combinations 
with one another, and in high doses when compared to 
other antihypertensive drugs.
The exact mechanism and long-term clinical implications 
of new-onset diabetes is currently being debated. The 
dismetabolic effects of diuretics and beta blockers could 
be dose dependent. There is indirect trial evidence that 
diuretics (thiazide type), in doses from 25-50 mg and higher, 
are associated with increased incidence of new-onset 
DM, particularly when combined with high doses of beta 
blockers, e.g. 100 mg of atenolol. A recent meta-analysis 
of seven studies in almost 60 000 patients showed that, 
compared to beta blockers and diuretics, RAS blockers 
decreased the occurrence of new- onset diabetes by 20% 
(p < 0.001), while calcium antagonists decreased the onset 
of diabetes by 16% (p < 0.001).
A comparison was made in a 16-year follow-up of almost 
800 initially untreated hypertensive patients, of whom 6.5% 
had diabetes at the onset, and 5.8% developed new-onset 
diabetes following treatment. The risk of cardiovascular 
disease was similar in the group with pre-existing diabetes 
to that of the group who developed new-onset diabetes 
following treatment for hypertension. This suggests that 
the development of diabetes while on antihypertensive 
treatment increases cardiovascular risk. It could be that 
the combination of a low-dose diuretic with a blocker of 
the RAS or a calcium-channel blocker may prevent the 
metabolic deleterious effects of a thiazide diuretic.
Hypertension treatment as part of a global 
cardiovascular risk reduction
Cardiovascular risk factors tend to cluster and insulin 
resistance, type 2 diabetes mellitus, obesity and 
hypertension can be common in the same patient. 
Metformin, used to lower glucose, reduces cardiovascular 
risk in type 2 diabetes mellitus and also reduces the risk 
of a cardiovascular events in established macrovascular 
disease.
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The British guidelines suggest a reduction of low-density 
lipoprotein (LDL) cholesterol to < 2 mmol/L in type 2 
diabetes mellitus patients using a statin. A meta-analysis 
of 12 randomised control clinical trials demonstrated that 
in both primary and secondary prevention, diabetics had 
similar cardiovascular risk reductions to non-diabetics 
when using a statin. Thus, the vast majority, if not all, of type 
2 diabetes mellitus patients should receive a statin.
The aim of therapy is to reduce overall cardiovascular risk by 
targeting blood pressure reduction, blood sugar reduction, 
smoking cessation and adding a statin in all diabetics.
Summary of treatment
• The blood pressure goal is 130/80 mmHg.
• Multiple drugs are best to achieve target blood pressure.
• ACE inhibitors or ARBs should be part of the regimen.
• In type 1 diabetes mellitus with any degree of albuminuria, 
an ACE inhibitor/ARB is necessary.
• In type 2 diabetes mellitus with any degree of albuminuria, 
an ACE inhibitor/ARB is necessary, especially with renal 
insufficiency.
• Start with ACE inhibitors or ARBs. If systolic blood 
pressure is > 20 mmHg higher than the goal of 
130 mmHg, add a diuret
• ic or calcium-channel blocker. If still uncontrolled, add 
an ACE-I or ARB, plus diuretic, plus calcium channel 
blocker. If still uncontrolled, add an aldosterone-receptor 
blocker.
• Add a statin to reduce macrovascular risk. 
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